Plus Therapeutics, Inc.(PSTV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PSTV Plus Therapeutics, Inc.

盘后交易 07-01 17:18:20 EDT

4.16

-0.21

-4.81%

盘后4.16

+0.000.00%

17:08 EDT

最高4.51	最低4.15	成交量13.89万
今开4.39	昨收4.37	日振幅8.24%
总市值2,855万	流通市值2,637万	总股本686.20万
成交额60.62万	换手率2.19%	流通股本633.95万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PSTV","market":"US","secType":"STK","nameCN":"Plus Therapeutics, Inc.","latestPrice":4.16,"timestamp":1782936000000,"preClose":4.37,"halted":0,"volume":138921,"hourTrading":{"tag":"盘后","latestPrice":4.16,"preClose":4.16,"latestTime":"17:08 EDT","volume":703,"amount":2935.693553,"timestamp":1782940115765,"change":0,"changeRate":0,"amplitude":0.012019},"delay":0,"changeRate":-0.04805491990846681,"floatShares":6339500,"shares":6862000,"eps":-2.616304,"marketStatus":"盘后交易","change":-0.21,"latestTime":"07-01 17:18:20 EDT","open":4.39,"high":4.51,"low":4.15,"amount":606210.0817077,"amplitude":0.08238,"askPrice":4.2,"askSize":84,"bidPrice":4.1,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.616304,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782950400000},"marketStatusCode":4,"adr":0,"listingDate":1134968400000,"exchange":"NASDAQ","adjPreClose":4.37,"preHourTrading":{"tag":"盘前","latestPrice":4.38,"preClose":4.37,"latestTime":"09:29 EDT","volume":2362,"amount":10247.514561,"timestamp":1782912595315,"change":0.01,"changeRate":0.002288,"amplitude":0.050458},"postHourTrading":{"tag":"盘后","latestPrice":4.16,"preClose":4.16,"latestTime":"17:08 EDT","volume":703,"amount":2935.693553,"timestamp":1782940115765,"change":0,"changeRate":0,"amplitude":0.012019},"volumeRatio":0.379056},"requestUrl":"/m/hq/s/PSTV","defaultTab":"news","newsList":[{"id":"1147341505","title":"Plus Therapeutics签订股权分销协议 涉及高达1735万美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1147341505","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147341505?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:12","pubTimestamp":1780395149,"startTime":"0","endTime":"0","summary":"根据一份向美国证券交易委员会提交的文件，生物制药公司Plus Therapeutics, Inc. 已签订一项股权分销协议。该协议涉及公司可通过销售其普通股筹集高达1735万美元的资金。\n此项安排为Plus Therapeutics提供了一种灵活的融资机制，使其能够在未来根据市场条件和公司需求，通过指定的销售代理逐步出售股票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147534136","title":"Plus公司Cnside诊断平台显著降低软脑膜转移患者医疗成本","url":"https://stock-news.laohu8.com/highlight/detail?id=1147534136","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147534136?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:33","pubTimestamp":1779795225,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司研发的Cnside诊断平台在针对软脑膜转移患者的应用中展现出显著的医疗成本节约效果。该平台通过精准诊断和优化治疗方案，有效减少了相关医疗支出，为患者及医疗系统带来了实质性的经济负担减轻。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170472306","title":"Plus Therapeutics公布Reyobiq™临床与转化数据口头报告：软脑膜转移治疗展现良好安全性、生存获益及免疫调节潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1170472306","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170472306?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:31","pubTimestamp":1778239880,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司近日宣布，将在重要学术会议上进行Reyobiq™治疗软脑膜转移瘤的口头报告。该报告将重点展示其在临床试验和转化研究中的关键数据，证实该疗法具有显著的安全性优势、令人鼓舞的生存获益表现以及初步显现的免疫调节作用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112786807","title":"Plus Therapeutics获蓝盾加州承保 将Cnside®脑脊液检测纳入转移性中枢神经系统癌覆盖范围","url":"https://stock-news.laohu8.com/highlight/detail?id=1112786807","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112786807?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:34","pubTimestamp":1777376052,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司宣布，其Cnside脑脊液检测试剂已正式获得蓝盾加州的保险覆盖，该检测主要用于转移性中枢神经系统癌症的诊断。这一突破性进展意味着符合条件的参保患者在进行相关检测时，将能够获得保险赔付，显著减轻医疗负担。此次获得蓝盾加州的承保认可，不仅体现了该检测技术的临床价值，也将进一步推动其在医疗实践中的广泛应用。对于Plus Therapeutics而言，这一里程碑事件标志着公司产品商业化进程取得重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102766857","title":"Plus Therapeutics与Spectronrx启动生产合作 为Reyobiq™关键性GMP试验铺平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1102766857","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102766857?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:30","pubTimestamp":1776943850,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司已正式启动与Spectronrx的生产协作，双方依据主服务协议展开合作，旨在为Reyobiq™的关键性GMP试验做好全面准备。这一战略性举措标志着该疗法向商业化应用迈出重要一步，为后续临床试验的顺利实施奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127842530","title":"Plus Therapeutics公司Reyobiq™获美国FDA儿科恶性胶质瘤孤儿药认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127842530","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127842530?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:30","pubTimestamp":1775647814,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司近日宣布，其研发的药物Reyobiq™已获得美国食品药品监督管理局（FDA）授予的孤儿药认定，用于治疗儿科恶性胶质瘤。这一认定有望加速该药物在罕见儿科疾病领域的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184710730","title":"Plus Therapeutics获AMA PLA编码授权，推动Cnside®脑脊液肿瘤细胞计数检测在美国的商业化与医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1184710730","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184710730?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:33","pubTimestamp":1775561589,"startTime":"0","endTime":"0","summary":"Plus Therapeutics, Inc. 近日宣布，其Cnside®脑脊液肿瘤细胞计数检测已获得美国医学会（AMA）颁发的专属实验室分析（PLA）编码。这一重要进展将显著促进该检测在美国市场的医保报销进程与商业应用推广。\nPLA编码的授予为Cnside®检测的广泛临床采用奠定了坚实基础，标志着其在精准肿瘤诊断领域迈出了关键一步。此举预计将优化检测服务的报销流程，加速其融入美国主流医疗体系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197448630","title":"Maxim集团调整Plus Therapeutics目标价至12美元，反映1合25的反向拆股","url":"https://stock-news.laohu8.com/highlight/detail?id=1197448630","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197448630?lang=zh_cn&edition=full","pubTime":"2026-04-07 12:03","pubTimestamp":1775534593,"startTime":"0","endTime":"0","summary":"投资机构Maxim集团近日宣布，对生物制药公司Plus Therapeutics, Inc.的目标股价进行调整，从原先的37.5美元下调至12美元。此次调整主要反映了该公司近期实施的1股合25股的反向股票分割措施。反向拆股后，公司总股本数量相应减少，每股价格按比例提升，因此目标价需进行技术性修正，以保持估值基准的一致性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102805000","title":"Plus Therapeutics任命诊断与分子诊断行业领袖Ron Andrews加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1102805000","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102805000?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:31","pubTimestamp":1774524672,"startTime":"0","endTime":"0","summary":"Plus Therapeutics, Inc. 宣布任命诊断与分子诊断领域的资深行业领袖Ron Andrews加入其董事会。这一重要人事任命将进一步增强公司在精准医疗领域的战略布局与专业领导力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199335711","title":"Plus Therapeutics宣布对流增强递送联合Reyobiq™获新III类CPT代码","url":"https://stock-news.laohu8.com/highlight/detail?id=1199335711","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199335711?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:39","pubTimestamp":1772023184,"startTime":"0","endTime":"0","summary":"生物制药公司Plus Therapeutics, Inc.近日披露，其创新疗法Reyobiq™结合的对流增强递送技术已获得美国医学会颁发的III类现行 procedural terminology代码。这一专业编码将显著优化该技术在美国医疗报销体系中的申报流程。\n新代码的设立意味着采用该递送技术的医疗机构能够更精准地进行费用结算，为后续商业化推广奠定基础。对流增强递送技术能突破血脑屏障，实现治疗剂量的精准靶向投递，目前正应用于神经胶质瘤等中枢神经系统疾病的临床试验阶段。\n此次编码获批标志着该技术向标准化临床应用迈出关键一步。公司表示将积极推进相关医保覆盖工作，加速创新疗法的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122404931","title":"Plus Therapeutics, Inc.：预计2026年完成复发性胶质母细胞瘤二期试验的患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1122404931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122404931?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:38","pubTimestamp":1772023091,"startTime":"0","endTime":"0","summary":"Plus Therapeutics, Inc. 在复发性胶质母细胞瘤二期临床试验的招募进度上，正稳步按照预定计划推进，预计将于2026年完成全部患者入组工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114735594","title":"Plus Therapeutics发布Reyobiq™临床项目及Cnside®美国商业化业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1114735594","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114735594?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:45","pubTimestamp":1769085945,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司近日就其核心产品Reyobiq™的临床研发计划以及Cnside®在美国市场的商业化布局，向投资者同步了最新业务动态。此次更新涵盖了临床试验的关键节点与市场推广的战略路径，展现出公司在肿瘤治疗领域的技术积累与商业化执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100660695","title":"Plus Therapeutics将于2026年1月22日周四上午9点（美国东部时间）举行业务更新电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1100660695","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100660695?lang=zh_cn&edition=full","pubTime":"2026-01-22 05:16","pubTimestamp":1769030174,"startTime":"0","endTime":"0","summary":"生物制药公司Plus Therapeutics, Inc.宣布，将于2026年1月22日周四美国东部时间上午9点举办业务进展通报会。届时管理层将详细介绍公司最新发展动态，并设有问答环节供投资者交流。此次电话会议将通过公司官网进行直播，并提供回放功能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605142258","title":"Plus Therapeutics, Inc.盘中异动 股价大涨5.49%报0.304美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142258","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605142258?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:34","pubTimestamp":1768919666,"startTime":"0","endTime":"0","summary":"北京时间2026年01月20日22时34分，Plus Therapeutics, Inc.股票出现波动，股价急速拉升5.49%。Plus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.58%。其相关个股中，Corvus Pharmaceuticals, Inc.、Rapt Therapeutics, Inc.、Aclaris Therapeutics, Inc.涨幅较大，Jaguar Health, Inc.、Dermata Therapeutics, Inc.、Rapt Therapeutics, Inc.较为活跃，换手率分别为60.83%、46.14%、44.42%，振幅较大的相关个股有Corvus Pharmaceuticals, Inc.、Immunitybio, Inc.、Aclaris Therapeutics, Inc.，振幅分别为18.14%、15.04%、14.50%。Plus Therapeutics, Inc.公司简介：Plus Therapeutics Inc是一家临床阶段制药公司，专注发现，开发和提供为癌症和罕见疾病患者提供复杂的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120223426a4418465&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120223426a4418465&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PSTVZ","PSTV","BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187321930","title":"Plus Therapeutics公司1月13日与Lake Street Capital Markets签订承销协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1187321930","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187321930?lang=zh_cn&edition=full","pubTime":"2026-01-17 05:09","pubTimestamp":1768597754,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司于1月13日宣布，已与Lake Street Capital Markets, LLC正式签署承销协议。该协议细节已通过美国证券交易委员会（SEC）文件对外披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156160775","title":"Plus Therapeutics宣布完成与美国FDA的B类会议，旨在加速Reyobiq™治疗软脑膜转移瘤的审批进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1156160775","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156160775?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:32","pubTimestamp":1767875537,"startTime":"0","endTime":"0","summary":"Plus Therapeutics公司近日公布，其已成功完成与美国食品药品监督管理局（FDA）举行的B类会议。此次会议的核心目标在于推动该公司旗下药物Reyobiq™用于治疗软脑膜转移瘤的加速审批流程。这一关键步骤标志着该疗法在监管路径上取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517148026","title":"股价一夜飙涨逾300%！Plus Therapeutics(PSTV.US)肺癌患者软脑膜转移药物获FDA孤儿药认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517148026","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517148026?lang=zh_cn&edition=full","pubTime":"2025-03-07 08:49","pubTimestamp":1741308551,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Plus Therapeutics周四表示，其针对肺癌患者软脑膜转移的治疗药物Rhenium  Obisbemeda获得美国食品药品监督管理局孤儿药认定。受此提振，该公司股价周四收涨311.43%，盘后续涨超50%。FDA授予孤儿药认定的目的在于为针对罕见疾病和病症的药物研发者提供财务激励。除了临床试验费用的税收抵免和营销申请用户费用的豁免外，开发者还可以获得长达七年的美国市场独占权。Plus Therapeutics表示，这一认定是在公司近期完成早期单剂量试验后获得的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LENZ","PSTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517316983","title":"Plus Therapeutics, Inc.股价上涨63.46% 市值涨214.05万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517316983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517316983?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271503,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Plus Therapeutics, Inc.股票出现异动，股价快速上涨63.46%。Plus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Plus Therapeutics, Inc.、Exicure, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为945.74%、102.53%、48.57%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Astria Therapeutics, Inc.，振幅分别为24.20%、13.05%、11.88%。Plus Therapeutics, Inc.公司简介：Plus Therapeutics Inc是一家临床阶段制药公司，专注发现，开发和提供为癌症和罕见疾病患者提供复杂的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223143abeb7782&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223143abeb7782&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PSTV","PSTVZ","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517989943","title":"Plus Therapeutics, Inc.盘中异动 早盘股价大涨10.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517989943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517989943?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:31","pubTimestamp":1741185095,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时31分，Plus Therapeutics, Inc.股票出现波动，股价急速上涨10.69%。Plus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Chimerix, Inc.、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为334.68%、252.30%、185.70%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Tango Therapeutics, Inc.，振幅分别为23.90%、13.51%、11.41%。Plus Therapeutics, Inc.公司简介：Plus Therapeutics Inc是一家临床阶段制药公司，专注发现，开发和提供为癌症和罕见疾病患者提供复杂的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223135a260c738&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223135a260c738&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PSTVZ","PSTV","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516963757","title":"Plus Therapeutics, Inc.盘中异动 急速跳水6.19%报0.680美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516963757","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516963757?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:50","pubTimestamp":1741013451,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时50分，Plus Therapeutics, Inc.股票出现波动，股价大幅下跌6.19%。Plus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为508.31%、113.64%、83.90%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为140.46%、70.53%、35.60%。Plus Therapeutics, Inc.公司简介：Plus Therapeutics Inc是一家临床阶段制药公司，专注发现，开发和提供为癌症和罕见疾病患者提供复杂的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225052a25d45b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225052a25d45b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PSTVZ","BK4139","PSTV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.plustherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0711},{"period":"1month","weight":-0.2491},{"period":"3month","weight":0.122},{"period":"6month","weight":-0.6588},{"period":"1year","weight":-0.4974},{"period":"ytd","weight":-0.6588}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":-0.0128},{"period":"3month","weight":0.1397},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Plus Therapeutics, Inc.最初于1996年7月成立为加利福尼亚州普通合伙企业，并于1997年5月在特拉华州注册成立。该公司是一家美国医疗保健公司，致力于开发和商业化用于中枢神经系统（“CNS”）癌症的精确诊断和靶向放射性药物。CNSide Diagnostics, LLC是其全资子公司，开发和商业化专有实验室开发的测试，如CNSide，旨在识别癌症和黑色素瘤患者中转移到中枢神经系统的肿瘤细胞。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.059718},{"month":2,"riseRate":0.541667,"avgChangeRate":0.032207},{"month":3,"riseRate":0.375,"avgChangeRate":-0.062118},{"month":4,"riseRate":0.375,"avgChangeRate":-0.005258},{"month":5,"riseRate":0.458333,"avgChangeRate":0.34396},{"month":6,"riseRate":0.24,"avgChangeRate":-0.083556},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.003883},{"month":8,"riseRate":0.291667,"avgChangeRate":-0.04175},{"month":9,"riseRate":0.541667,"avgChangeRate":-0.030103},{"month":10,"riseRate":0.291667,"avgChangeRate":-0.062759},{"month":11,"riseRate":0.375,"avgChangeRate":0.007725},{"month":12,"riseRate":0.375,"avgChangeRate":-0.028095}],"exchange":"NASDAQ","name":"Plus Therapeutics, Inc.","nameEN":"Plus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Plus Therapeutics, Inc.(PSTV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Plus Therapeutics, Inc.(PSTV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Plus Therapeutics, Inc.,PSTV,Plus Therapeutics, Inc.股票,Plus Therapeutics, Inc.股票老虎,Plus Therapeutics, Inc.股票老虎国际,Plus Therapeutics, Inc.行情,Plus Therapeutics, Inc.股票行情,Plus Therapeutics, Inc.股价,Plus Therapeutics, Inc.股市,Plus Therapeutics, Inc.股票价格,Plus Therapeutics, Inc.股票交易,Plus Therapeutics, Inc.股票购买,Plus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Plus Therapeutics, Inc.(PSTV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Plus Therapeutics, Inc.(PSTV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}